On March 19th, at the MDA Clinical and Scientific Conference in Dallas, TX, Dr. Cornett will present exciting findings from the wearable sensor study conducted in collaboration with HNF’s partner, BioSensics. This innovative research highlights the potential of wearable technology to transform how disease progression and therapy effectiveness are measured for individuals with CMT.
Looking for new patients to participate in the BioSensics Wearable Study. Join us in Nashville, TN, April 24-26th.
#GivingTuesday unites countries around the world by sharing our capacity to care for and empower one another, and using the power of social media to amplify the small acts of kindness by organizations, families, and individuals.
HNF has invited Kerin Reilly, who sits on our Board of Directors, to join us on the panel discussion “The Fearless Caregiver: The Caregiver’s Voice Matters and the Role of the Caregiver in Patient-Driven Research.”
The Hereditary Neuropathy Foundation is currently seeking 10 second video clips of CMT patients under the age of 16, performing daily activities.
Bracing is used in the management Charcot-Marie-Tooth to support and hold a part of the body compromised by muscle weakness, muscular atrophy, sensory impairment. Bracing is also used to help correct skeletal deformity.
Dr. Arnold is currently President & CEO, Arnold Consultancy & Technology LLC, eadquartered in New York City, and Practice Lead, HEOR, Quorum Consulting, Inc., based in San Francisco, CA
With respect to CMT, Dr. Baker’s team has collaborated with Drs. Michael Sereda and Klaus Nave of the Max Planck Institute for Experimental Medicine (MPI) to utilize their CMT1A transgenic rat and established the initial CMT1A rat colony in the United States.
Dr. Steven J. Gray is an Assistant Professor in the Dept. of Ophthalmology, U. of N. Carolina at Chapel Hill.
Bernadette Scarduzio – a CMT patient and advocate! I reside in Drexel Hill, PA with my 2 dogs.
John is Founder and Managing Director of Infusion Pharma Consulting LLC, a leading business strategy consultancy focused on the Orphan Drug and Hospital Therapeutics
Dr. Liu shares the consensus that CMT is a lesser known disease and more research is needed to shed light on the experiences of patients with CMT.
0 Comments